A Personalized Approach to Perioperative Immunotherapy in Early-Stage Resectable NSCLC

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Personalized Approach to Perioperative Immunotherapy in Early-Stage Resectable NSCLC 

4 episodes
0.50 program credits
ReachMD Healthcare Image
Choose a format
Take Program Post-Test
Program Post-Test Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This educational activity highlights the latest advancements in perioperative immunotherapy for early-stage non-small cell lung cancer and emphasizes the importance of accurate staging, molecular profiling, and a multidisciplinary approach. By integrating recent clinical trial data and expert insights, healthcare professionals will learn to evaluate and apply emerging evidence to optimize individualized treatment strategies. Explore the evolving landscape of neoadjuvant and adjuvant chemoimmunotherapy while gaining critical knowledge to improve patient outcomes through collaborative, evidence-based care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mark Awad, MD, PhD
    Associate Professor of Medicine
    Harvard Medical School
    Associate Chief of the Lowe Center, Thoracic Oncology
    Dana-Farber Cancer Institute
    Boston, MA

    Dr. Awad has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research support: Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; and Lilly
    Consulting fees: Affini-T; AstraZeneca; Blueprint Medicines Corporation; Bristol Myers Squibb; EMD Serono, Inc.; Genentech Inc.; Janssen; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Novartis Pharmaceuticals Corporation 

    Jessica Donington, MD
    Professor of Surgery
    Chief of the Section of Thoracic Surgery
    The University of Chicago
    Chicago, IL

    Dr. Donington has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting fees: Amgen, AstraZeneca, BMS, Merck, Roche/Genentech

    Reviewers/Content Planners/Authors:

    • Rebecca Barraclough has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Bob Garris has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Victor Ocana has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate current and emerging evidence on the efficacy and safety of perioperative immunotherapy regimens in early-stage resectable non-small cell lung cancer (NSCLC) 
    • Design personalized care strategies that incorporate patient and disease characteristics and the latest evidence involving immunotherapy-based approaches to manage patients with early-stage NSCLC
  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists and thoracic surgeons, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 6/28/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. 


    Global Learning Collaborative (GLC) designates this activity for 0.5 contact hours/0.05 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-065-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ( 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Jul 2024